Definitive Healthcare Corp. (NASDAQ:DH) Given Consensus Rating of "Reduce" by Analysts

Key Points

• Analysts maintain a consensus “Reduce” rating on Definitive Healthcare, with three sell ratings, five holds and one strong buy. The average 12-month price target is $1.47.
• Shares opened at $0.73, near the lower end of their 52-week range of $0.61 to $4.35. The company recently reported quarterly EPS of $0.05, beating estimates, but revenue of $55.2 million fell slightly short of expectations and net margin remained negative.
• Institutional investors own 98.67% of the stock, with several funds recently increasing their positions, including BNP Paribas Financial Markets, the Alaska Department of Revenue and Creative Planning.

Definitive Healthcare Corp. (NASDAQ:DH - Get Free Report) has received a consensus rating of "Reduce" from the nine analysts that are covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a sell recommendation, five have issued a hold recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $1.4714.

Several research analysts recently commented on the stock. Wall Street Zen raised shares of Definitive Healthcare from a "hold" rating to a "buy" rating in a report on Sunday, July 26th. Bank of America reissued an "underperform" rating and set a $0.70 target price on shares of Definitive Healthcare in a report on Monday, June 29th. Robert W. Baird set a $1.10 target price on Definitive Healthcare in a research report on Friday, May 8th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Definitive Healthcare in a report on Wednesday, June 3rd. Finally, Zacks Research upgraded Definitive Healthcare from a "strong sell" rating to a "hold" rating in a research report on Tuesday, April 28th.

Definitive Healthcare Trading Up 1.3%

Shares of Definitive Healthcare stock opened at $0.73 on Friday. Definitive Healthcare has a 52-week low of $0.61 and a 52-week high of $4.35. The stock's 50-day simple moving average is $0.74 and its 200 day simple moving average is $1.01. The stock has a market capitalization of $77.66 million, a P/E ratio of -0.45, a P/E/G ratio of 11.59 and a beta of 1.35. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.86 and a current ratio of 1.86.

Definitive Healthcare (NASDAQ:DH - Get Free Report) last released its quarterly earnings data on Monday, August 10th. The company reported $0.05 EPS for the quarter, beating the consensus estimate of $0.04 by $0.01. The business had revenue of $55.20 million for the quarter, compared to the consensus estimate of $55.47 million. Definitive Healthcare had a negative net margin of 72.28% and a positive return on equity of 3.55%. Definitive Healthcare has set its FY 2026 guidance at 0.180-0.200 EPS and its Q3 2026 guidance at 0.040-0.050 EPS. As a group, research analysts anticipate that Definitive Healthcare will post 0.04 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in DH. BNP Paribas Financial Markets grew its holdings in shares of Definitive Healthcare by 32.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 17,811 shares of the company's stock valued at $72,000 after purchasing an additional 4,407 shares during the last quarter. State of Alaska Department of Revenue lifted its stake in Definitive Healthcare by 109.3% in the fourth quarter. State of Alaska Department of Revenue now owns 11,433 shares of the company's stock worth $32,000 after purchasing an additional 5,970 shares during the last quarter. Invesco Ltd. boosted its position in Definitive Healthcare by 5.8% during the fourth quarter. Invesco Ltd. now owns 117,427 shares of the company's stock valued at $337,000 after buying an additional 6,400 shares during the period. Raymond James Financial Inc. purchased a new stake in Definitive Healthcare during the second quarter valued at about $32,000. Finally, Creative Planning grew its stake in shares of Definitive Healthcare by 41.7% during the second quarter. Creative Planning now owns 28,628 shares of the company's stock valued at $112,000 after buying an additional 8,428 shares during the last quarter. Hedge funds and other institutional investors own 98.67% of the company's stock.

Definitive Healthcare Company Profile

Definitive Healthcare NASDAQ: DH is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company's flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source